Lead Product(s) : SOM3355
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SOM Biotech Granted Orphan Drug Designation by the FDA for SOM3355
Details : SOM3355 has potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease.
Product Name : SOM3355
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : SOM3355
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SOM3355
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SOM Biotech Presents Positive Phase 2a Data With SOM3355 at the 34thECNP Congress 2021
Details : SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of chorea movements associated with Huntington’s disease (HD).
Product Name : SOM3355
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2021
Lead Product(s) : SOM3355
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 NEXUS trial aims at evaluating the safety and efficacy of leriglitazone in pediatric patients with early-stage cerebral ALD (cALD), the acute form of X-linked adrenoleukodystrophy (X-ALD).
Product Name : MIN-102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable